These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2334 related articles for article (PubMed ID: 31042825)
1. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825 [TBL] [Abstract][Full Text] [Related]
2. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A; Moreau P; Yakoub-Agha I; Delforge M; Cavo M; Einsele H; Goldschmidt H; Weisel K; Rambaldi A; Reece D; Petrocca F; Massaro M; Connarn JN; Kaiser S; Patel P; Huang L; Campbell TB; Hege K; San-Miguel J N Engl J Med; 2021 Feb; 384(8):705-716. PubMed ID: 33626253 [TBL] [Abstract][Full Text] [Related]
3. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Li C; Cao W; Que Y; Wang Q; Xiao Y; Gu C; Wang D; Wang J; Jiang L; Xu H; Xu J; Zhou X; Hong Z; Wang N; Huang L; Zhang S; Chen L; Mao X; Xiao M; Zhang W; Meng L; Cao Y; Zhang T; Li J; Zhou J Clin Transl Med; 2021 Mar; 11(3):e346. PubMed ID: 33784005 [TBL] [Abstract][Full Text] [Related]
4. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333 [TBL] [Abstract][Full Text] [Related]
5. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study. Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477 [TBL] [Abstract][Full Text] [Related]
6. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021 [TBL] [Abstract][Full Text] [Related]
7. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Wang D; Wang J; Hu G; Wang W; Xiao Y; Cai H; Jiang L; Meng L; Yang Y; Zhou X; Hong Z; Yao Z; Xiao M; Chen L; Mao X; Zhu L; Wang J; Qiu L; Li C; Zhou J Blood; 2021 May; 137(21):2890-2901. PubMed ID: 33512480 [TBL] [Abstract][Full Text] [Related]
8. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Zhang M; Wei G; Zhou L; Zhou J; Chen S; Zhang W; Wang D; Luo X; Cui J; Huang S; Fu S; Zhou X; Tang Y; Ding X; Kuang J; He XP; Hu Y; Huang H Lancet Haematol; 2023 Feb; 10(2):e107-e116. PubMed ID: 36725117 [TBL] [Abstract][Full Text] [Related]
9. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J Front Immunol; 2021; 12():755866. PubMed ID: 34777368 [TBL] [Abstract][Full Text] [Related]
10. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851 [TBL] [Abstract][Full Text] [Related]
11. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319 [TBL] [Abstract][Full Text] [Related]
12. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. Oliver-Caldés A; González-Calle V; Cabañas V; Español-Rego M; Rodríguez-Otero P; Reguera JL; López-Corral L; Martin-Antonio B; Zabaleta A; Inogés S; Varea S; Rosiñol L; López-Díaz de Cerio A; Tovar N; Jiménez R; López-Parra M; Rodríguez-Lobato LG; Sánchez-Salinas A; Olesti E; Calvo-Orteu M; Delgado J; Pérez-Simón JA; Paiva B; Prósper F; Sáez-Peñataro J; Juan M; Moraleda JM; Mateos MV; Pascal M; Urbano-Ispizua A; Fernández de Larrea C Lancet Oncol; 2023 Aug; 24(8):913-924. PubMed ID: 37414060 [TBL] [Abstract][Full Text] [Related]
13. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681 [TBL] [Abstract][Full Text] [Related]
14. GPRC5D-Targeted CAR T Cells for Myeloma. Mailankody S; Devlin SM; Landa J; Nath K; Diamonte C; Carstens EJ; Russo D; Auclair R; Fitzgerald L; Cadzin B; Wang X; Sikder D; Senechal B; Bermudez VP; Purdon TJ; Hosszu K; McAvoy DP; Farzana T; Mead E; Wilcox JA; Santomasso BD; Shah GL; Shah UA; Korde N; Lesokhin A; Tan CR; Hultcrantz M; Hassoun H; Roshal M; Sen F; Dogan A; Landgren O; Giralt SA; Park JH; Usmani SZ; Rivière I; Brentjens RJ; Smith EL N Engl J Med; 2022 Sep; 387(13):1196-1206. PubMed ID: 36170501 [TBL] [Abstract][Full Text] [Related]
15. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T. Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700 [TBL] [Abstract][Full Text] [Related]
16. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Cowan AJ; Pont MJ; Sather BD; Turtle CJ; Till BG; Libby EN; Coffey DG; Tuazon SA; Wood B; Gooley T; Wu VQ; Voutsinas J; Song X; Shadman M; Gauthier J; Chapuis AG; Milano F; Maloney DG; Riddell SR; Green DJ Lancet Oncol; 2023 Jul; 24(7):811-822. PubMed ID: 37414012 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596 [No Abstract] [Full Text] [Related]
18. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. Zhao WH; Liu J; Wang BY; Chen YX; Cao XM; Yang Y; Zhang YL; Wang FX; Zhang PY; Lei B; Gu LF; Wang JL; Yang N; Zhang R; Zhang H; Shen Y; Bai J; Xu Y; Wang XG; Zhang RL; Wei LL; Li ZF; Li ZZ; Geng Y; He Q; Zhuang QC; Fan XH; He AL; Zhang WG J Hematol Oncol; 2018 Dec; 11(1):141. PubMed ID: 30572922 [TBL] [Abstract][Full Text] [Related]
19. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997 [TBL] [Abstract][Full Text] [Related]
20. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma. Li C; Xu J; Luo W; Liao D; Xie W; Wei Q; Zhang Y; Wang X; Wu Z; Kang Y; Zheng J; Xiong W; Deng J; Hu Y; Mei H Leukemia; 2024 Jan; 38(1):149-159. PubMed ID: 37848634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]